tbuckley/cabot-search huggingface dataset:
Freezing Bone Without Excision
Authors: Andrew A. Gage
Journal: JAMA (1966)

Freezing is lethal for cells and may be used to destroy normal or neoplastic tissue.<sup>1,2</sup>Our experience with cryotherapy for malignant tumors in the oral cavity demonstrated that lesions which were radioresistant and were not amenable to excision could be controlled.<sup>3</sup>When the cancer was adjacent to the mandible or maxilla, the bone also was frozen during treatment and was exposed when the soft tissue sloughed a few days later. Although the bared bone became discolored and coated with necrotic debris, healing occurred and soft tissue slowly covered the area. These observations suggested an experimental study to determine the extent of cell destruction and the manner of subsequent regrowth in bone devitalized by freezing without having been removed from the body. The purpose of the experiments was the development and evaluation of a technique of treating bone tumors without amputation or excision. <h3>Methods and Materials</h3> The femora of
Tuberculosis: Yesterday, Today, and Tomorrow
Authors: John A. Sbarbaro
Journal: Annals of Internal Medicine (1996)

Letters15 February 1996Tuberculosis: Yesterday, Today, and TomorrowJohn A. Sbarbaro, MD, MPHJohn A. Sbarbaro, MD, MPHUniversity of Colorado Health Sciences Center; Denver, CO 80262Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-124-4-199602150-00017 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:Riley and colleagues present an interesting question. Should a “standard of care” that has emerged from 30 years of heated professional debate, randomized treatment trials, retrospective case studies, and thoughtful consensus by experienced, knowledgeable physicians be sacrificed because of the lack of knowledge and possible poor judgment of a single provider? The obvious answer is no. If such decisions were made on the basis of such anecdotal incidents, no drug would be acceptable.As noted, drug reactions related to rifampin were first reported in 1971. Familiarity with the older literature, however, is not a prerequisite for awareness of ...References1. Advisory Council for the Elimination of Tuberculosis. Initial therapy for tuberculosis in the era of multidrug resistance: recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR. 1993; 42:RR/7. Google Scholar2. WHO Report on the Tuberculosis Epidemic, 1995. WHO/TB/95.183 Distr: General (Available from the World Health Organization/Tuberculosis Programme, Geneva, Switzerland). Google Scholar3. Bayer R, Wilkinson D. Directly observed therapy for tuberculosis: history of an idea. Lancet. 1995; 345:1545-8. Google Scholar Author, Article, and Disclosure InformationAuthors: John A. Sbarbaro, MD, MPHAffiliations: University of Colorado Health Sciences Center; Denver, CO 80262 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 15 February 1996Volume 124, Issue 4 Page: 455-456 Keywords Adverse reactions Directly observed therapy Drug therapy Drugs Global health Hepatitis A Isoniazid Multidrug resistant tuberculosis Retrospective studies ePublished: 15 August 2000 Issue Published: 15 February 1996 Copyright & PermissionsCopyright © 1996 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Treatment of cutaneous metastases of Merkel cell carcinoma with surface-mold computer-optimized high-dose rate brachytherapy.
Authors: S. E. Cotter, P. M. Devlin, D. Sahni, A. K. Ng, L. C. Wang
Journal: Journal of Clinical Oncology (2010)

e19010 Background: Merkel cell carcinoma (MCC) is an aggressive cutaneous neuroendocrine carcinoma with great propensity for locoregional recurrence and distant metastases. Despite surgery and radiation therapy, lower extremity in-transit (and retrograde) cutaneous metastases are unfortunately common and present a therapeutic challenge. The often diffuse nature of lower extremity metastases renders negative margin excision unfeasible. Response to chemotherapy is limited and rarely durable. Although MCC is radiosensitive, radiation therapy is technically difficult for multifocal disease over the complex anatomic curvatures of the lower extremities. Methods: The Dana-Farber/Brigham and Women's Cancer Center has overcome these limitations with surface-mold computer-optimized high-dose rate brachytherapy (SMBT). Moldable applicators composed of a thermoplastic material and HDR treatment catheters are created for 3D conformal image-guided brachytherapy, which allows for the efficient and accurate targeting of high-dose rate radiation to multiple lesions with minimal toxicity. Results: We present an illustrative case of a 74-year-old man with 11 right lower extremity cutaneous metastases who was successfully treated with SMBT with 30-months follow-up. A total dose of 12 Gray was delivered by SMBT to each nodule in two equal fractions two days apart. All lesions, including two untreated lesions, resolved clinically and radiographically within a few weeks of treatment completion with no radiation side effects. The patient developed a single recurrence within the treated area 25 months after brachytherapy in the setting of diffuse metastatic disease. Clinical, radiographic and dosmetric images are provided. Conclusions: This is the first report describing the use of SMBT for controlling cutaneous metastatic MCC of the extremity, a challenging presentation with limited treatment options. Apart from providing effective palliation, this innovative therapy may have broader applications in the management of early-stage MCC. Further studies are warranted. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Nucletron
The T Cell Response To The Malaria Circumsporozoite Protein: An Immunological Approach To Vaccine Development
Authors: M. Good
Journal: Annual Review of Immunology (1988)

Exhausted CD8 T (Tex) cells are a distinct cell lineage that arise during chronic infections and cancers in animal models and humans. Tex cells are characterized by progressive loss of effector functions, high and sustained inhibitory receptor expression, ...Read More
Journal American Dental Association, Chicago
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Transforming growth factor β1-regulated gene expression of Ito cells
Authors: T Knittel
Journal: Hepatology (1996)

During liver fibrogenesis, Ito cells are regarded as the principal matrix synthesizing cells and transforming growth factor β 1 (TGF-β 1) appears to be the main fibrogenic mediator. This study analyzed the effects of TGF-β 1 on Ito cell activation, proliferation, and on the expression of a set of matrix proteins, antiproteases, and TGF-β receptors both in "early cultured" and "culture-activated" Ito cells. Rat liver Ito cells at day 2 of primary culture ("early cultured" cells) were mainly smooth muscle α actin (SMA)-negative, whereas cells at day 6 were judged as "activated" cells (SMA-positive). Following 24-hour exposure to 1 ng/mL TGF-β1, total protein synthesis, cell proliferation, and expression of the "activation" marker SMA were not significantly changed. In addition to previously described stimulatory effects on collagen types I and III, fibronectin, undulin, and proteoglycan-gene expression, TGF-β also dose-dependently increased synthesis and secretion of tenascin, laminin, entactin, collagen type IV, and α2-macroglobulin, but decreased C1-esterase inhibitor production by Ito cells, as revealed by immunoprecipitation of endogenously labeled proteins and by Northern blot analysis. The stimulatory effect of TGF-β was evident both in "early cultured" as well as "culture-activated" Ito cells. By reverse- transcription polymerase chain reaction (RT-PCR) analysis, TGF-β type II, III, and TGF-β/activin type I receptors were present in Ito cells, and their expression pattern was not changed upon TGF-β exposure. Northern blot analysis demonstrated that type I TGF-β/activin receptor was induced during in vitro activation and that TGF-β exposure resulted in a slight increase of type I and III receptor messenger RNAs. In summary, the data illustrate that TGF-β is an important fibrogenic mediator acting both on "early cultured" as well as "culture-activated" Ito cells, rather than a mitogenic or morphogenic mediator. The differential regulation of TGF-β/activin receptors during in vitro activation and their up-regulation by TGF-β1 might represent a mechanism by which the receptor complex regulates TGF-β signalling in Ito cells.
Omission of Conflicts of Interest
Authors: Richard Hoehn
Journal: JAMA Surgery (2016)

Michaela Kollisch-Singule, MD; Bryanna Emr, MD; Bradford Smith, PhD; Shreyas Roy, MD; Sumeet Jain, MD; Joshua Satalin, BS; Kathy Snyder; Penny Andrews, RN; Nader Habashi, MD; Jason Bates, PhD; William Marx, DO; Gary Nieman, BA; Louis A. Gatto, PhD
Modified Dialyzer Used For Relief Of Ascites
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The total artificial heart as a bridge to transplantation. A report of two cases
Authors: J. G. Copeland
Journal: JAMA (1986)

In 1985, at the University of Arizona, Tucson, two attempts were made to "bridge" patients from impending death to heart transplantation, using orthotopically positioned total artificial hearts. The first attempt, using an unapproved device on an emergency basis, failed after transplantation because of severe pulmonary edema and<i>Pseudomonas</i>pneumonia and the apparent transmission of a<i>Pseudomonas</i>infection from donor to recipient. The second experience, using a Jarvik-7 device, led to stable support for nine days with one major complication, a reversible neurologic deficit with no associated computed tomographic scan abnormality. This patient survived cardiac transplantation and, after being successfully treated for complications, has made a full recovery and returned to full-time work. (<i>JAMA</i>1986;256:2991-2995)
Clinical Implications of ST-Segment Non-Resolution after Thrombolysis for Myocardial Infarction
Authors: L Bhatia, G J Clesham, D R Turner
Journal: Journal of the Royal Society of Medicine (2004)

Failed reperfusion after thrombolytic therapy for acute myocardial infarction is common and signifies a poor prognosis. We investigated the clinical consequences of non-resolution of the ST segment after thrombolytic therapy for acute ST-elevation myocardial infarction, in 85 consecutive patients admitted to a coronary care unit lacking rapid access to angioplasty. Failed thrombolysis was defined as <50% ST-segment resolution 180 minutes after the start of thrombolytic treatment. Outcomes were measured in terms of in-hospital adverse events, length of hospital stay, and mortality at 6 weeks and 1 year. Thrombolysis was successful, in terms of ST-segment resolution, in 45 patients (53%). After adjustment for other factors, ST resolution was the only independent predictor of an uncomplicated recovery in hospital (odds ratio 6.8, 95% confidence interval 2.3 to 19.9; P<0.001). At 6 weeks and 1 year, overall mortality was lower in the ST resolution group, though these differences became non-significant on multivariate analysis. In patients who survived to hospital discharge, median length of stay was greater in successfully thrombolysed patients (9 days versus 8 days) despite their lower rate of complications. ST-segment resolution is a useful marker of successful thrombolysis and relates to clinical outcome. If assessed routinely it might assist, along with other clinical markers, in the identification of low-risk patients who can be discharged early.
Heart Failure
Authors: Janet M. Torpy
Journal: JAMA (2009)

Heart Failure H eart failure develops when the heart as a pump malfunctions.Systolic heart failure is the inability of the heart to squeeze enough blood from the ventricles (heart chambers) to supply the body' s needs.Diastolic heart failure results from the inability of the heart muscle to relax in between heartbeats, causing a backup of blood in the heart' s chambers and in the blood vessels.Both systolic and diastolic heart failure can cause edema (fluid) to build up in the lungs and the rest of the body.The heart tries to make up for this malfunction by dilating (enlarging the heart chambers) or becoming hypertrophic (thickening of the heart walls).For individuals older than 65 years, heart failure is the most common cause of hospitalization.The May 13, 2009, issue of JAMA contains an article about heart failure.
THE POISONS PRODUCED IN SUPERFICIAL BURNS.
Journal: JAMA (1906)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
BOOK REVIEWS
Authors: MYRON WINICK
Journal: JNCI Journal of the National Cancer Institute (1990)

Journal Article BOOK REVIEWS Get access Pregnancy Diet and Cancer . Bruce E. Walker . Bath, MI : McCuaig Publishing Co. , 1989 , 193 pp. $8.50. MYRON WINICK MYRON WINICK Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 82, Issue 12, 20 June 1990, Page 1064, https://doi.org/10.1093/jnci/82.12.1064 Published: 20 June 1990
Truth Telling in Medicine-Reply
Authors: Mark Sheldon
Journal: JAMA (1982)

<h3>In Reply.—</h3> Dr Verheecke's interesting comments were directed toward a case that I did not discuss—that of the incompetent patient. I can, however, essentially agree with his observations on this matter. I cannot, however, agree with the last statement in his letter, that "the real issue... is to tell the truth according to the patient's state of mind at the moment...." I think that one has an initial obligation to be as deliberately truthful as possible. Also, the basis on which one makes a judgment pertaining to the patient's "state of mind" would have to be examined carefully. This, at least, would be necessary to make me comfortable with this notion. Finally, in response to Dr Verheecke's concern about physicians who must practice in parts of the world where people suffer from an inability to talk openly about cancer, I think that physicians have the difficult and often painful obligation
Palliative Care Clinical Practice Guidelines in Oncology
Journal: Journal of the National Comprehensive Cancer Network (2003)

Over the past 20 years, increasing attention has been paid to quality-of-life issues in oncology. As the hospice movement has grown in this country, palliative care has developed into an integral part of comprehensive cancer care. The NCCN Palliative Care Guidelines were developed to facilitate the appropriate integration of palliative care into anticancer therapy. They were developed from the collaborative efforts of medical and surgical oncologists, neurologists, anesthesiologists, psychiatrists, internists, palliative care specialists, pastoral care counselors, social workers, and nurses. For the most recent version of the guidelines, please visit NCCN.org
Journal Amer Geriatrics Society, Baltimore
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Efficacy of sofosbuvir/velpatasvir (s/v): impact of treatment adherence
Authors: Tianna Magel, Chris Fraser, Sergio Borgia, Daniel Smyth, Curtis Cooper, Duncan Webster, Lisa Barrett, Kristoffer Stewart, Alexander Wong, Marie-Louise Vachon, Alnoor Ramji, Gisela Macphail, Abu Obeida Hamour, Leeanna Bulinckx, Edward Tam, Jordan Feld, Samuel Lee, Brian Conway
Journal: Journal of Hepatology (2020)
Brain Death
Authors: Janet M. Torpy
Journal: JAMA (2009)

Brain DeathA person dies when brain function ceases, the heart stops beating, and breathing and blood circulation cease.Because life-support techniques have become so advanced, it is possible that even in the face of fatal injury or unrecoverable illness, the heart can be kept beating with medication, and respiration (breathing) can be artificially performed with a ventilator.The concept of brain death developed in response to these advanced medical techniques that can maintain some bodily functions.Brain death, as understood in US law and medical practice, occurs when there is no function of the entire brain.The brainstem is the area of the brain that controls breathing and circulation and therefore controls essential life functions.When the brain, including the brainstem, has ceased to function, the individual is truly dead by medical and legal standards.Thus, brain death is real death.The March 18, 2009, issue of JAMA includes an article about brain death.This Patient Page is based on one published in the May 14, 2008, issue of JAMA.
Abstract 3612: Decreased vitamin C uptake mediated by <i>SLC2A3</i> promotes leukemia progression and impedes Tet2 restoration
Authors: Jun Liu, Junshik Hong, Kwangsung Ahn, Sungsoo Yoon
Journal: Cancer Research (2019)

Abstract Background: Two new studies in Nature and Cell, from Agathocleous et al. (2017) and Cimmino et al. (2017), respectively, showed that vitamin C regulates HSC function and suppresses leukemogenesis by modulating Tet2 activity. However, little is known about the relationship between vitamin C transporter and hematological malignancies. Purpose: In this study, we investigated the role of SLC2A3, a gene that encode GLUT3 which mainly transport glucose and oxidized form vitamin C, in hematological malignancies. Through this research we identified a set of biomarkers which can predict the effect of vitamin C treatment and develop stagey to improve this putative innovative treatment. Results: We analyzed gene expression patterns of the major GLUT family genes in primary AML blast cells using previously published microarray datasets (GSE37307) and (GSE9476) and determined that SLC2A3 gene expression was significantly decreased in blast cells compared with normal hematopoietic cells. By contrast, expression of SLC2A1, SLC2A2 and SLC23A2 was not significant different in between primary AML cells and normal hematopoietic cells. Next, we analyzed the relevance of SLC2A3 expression to the survival of AML patients from TCGA and TARGET database and found that below-median SLC2A3 expression was associated with inferior overall survival. Subsequently, we detected the SLC2A3 mRNA expression level on 4 AML cell lines and 3 DLBCL cell lines, there were very low expression level on OCI-AML-3 and OCI-LY1. To check whether decreased expression of SLC2A3 has an impact on the Vitamin C effect, we treated the 7 cell lines with dose dependent vitamin C, up to 500 μM, 48 hours. The cell viability assay showed that OCI-AML-3 and OCI-LY1 have no response to Vitamin C, however the proliferation of NB4, HEL, HL60, OCI-LY19 and Toledo was suppressed by 250 μM Vitamin C. Conclusions: SLC2A3 expression was decreased in AML blast cell and down regulation of SLC2A3 was closely associated with the poor outcomes of AML patients. In vitro study showed that SLC2A3 was essential for the effect of Vitamin C. Therefore, SLC2A3 could be a potential biomarker to predict the effect of Vitamin C treatment. In addition, through targeting SLC2A3, efficacy of Vitamin C treatment could be improved. Citation Format: Jun Liu, Junshik Hong, Kwangsung Ahn, Sungsoo Yoon. Decreased vitamin C uptake mediated by SLC2A3 promotes leukemia progression and impedes Tet2 restoration [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3612.